Literature DB >> 14622308

Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study.

Chia-Ti Tsai1, Shoei K Stephen Huang, Jiunn-Lee Lin, Ling-Ping Lai.   

Abstract

Little information about the ICD is available from the Asian Pacific region. The purpose of this study was to characterize the clinical features in ICD patients in Taiwan and to compare these features with those in patients in the Western populations, mainly the Canadian Implantable Defibrillator Study (CIDS), the Antiarrhythmics versus Implantable Defibrillator (AVID) trial, and the Cardiac Arrest Study Hamburg (CASH) trial. From February 1995 to October 2001, 101 ICDs were implanted in 92 patients (78 [84%] men) in 12 hospitals. Clinical presentations included sudden cardiac death due to VF/VT in 35 (38%) patients, syncopal VT in 25 (27%), drug refractory nonsyncopal VT in 27 (29%), and unexplained syncope with inducible sustained VT/VF in 5 (6%). The mean age was significantly younger than that in CIDS or AVID (59 +/- 16 vs 63 +/- 9 years in CIDS, P = 0.02; vs 65 +/- 11 years in AVID, P < 0.001), but was comparable to that in CASH (59 +/- 16 vs 58 +/- 11 years in CASH, P = 0.75). The mean LVEF was significantly higher than that in CIDS or AVID (48 +/- 19% vs 34 +/- 15% in CIDS, P < 0.001; vs 32 +/- 13% in AVID, P < 0.001), but was comparable to that in CASH (48 +/- 19 vs 46 +/- 19% in CIDS, P = 0.83). The ICD patients in the current study also showed a higher incidence of normal heart (23 vs 4% in CIDS, P < 0.001; vs 3% in AVID, P < 0.001; vs 9% in CASH, P < 0.001) and cardiomyopathy (41% vs 10% in CIDS, P < 0.001; vs 15% in AVID, P < 0.001; vs 11% in CASH, P < 0.001), but a lower incidence of coronary artery disease (29% vs 83% in CIDS, P < 0.001; vs 82% in AVID, P < 0.001; vs 73% in CASH, P < 0.001). During a mean follow-up of 28 +/- 24 months, 13 (14%) patients died. Older age was the only factor associated with poorer survival after ICD implantation. Forty-seven (51%) patients received appropriate ICD discharges during follow-up. History of prior myocardial infarction was the only factor associated with an earlier first appropriate ICD discharge and LVEF < 0.35 the only factor associated with subsequent poorer survival after the first ICD discharge. In conclusion, this study demonstrated many distinct clinical features in our ICD population that were different from those in the Western populations.

Entities:  

Mesh:

Year:  2003        PMID: 14622308     DOI: 10.1046/j.1460-9592.2003.00324.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  4 in total

1.  Management of patients with implantable cardioverter defibrillators at emergency departments.

Authors:  Chung-Pin Liu; Yi-Lwun Ho; Yen-Hung Lin; Yen-Bin Liu; Wei-Tien Chang; Chien-Hua Huang; Wen-Jone Chen
Journal:  Emerg Med J       Date:  2007-02       Impact factor: 2.740

2.  A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study.

Authors:  Sergio Dubner; Elina Valero; Ricardo Pesce; Jorge González Zuelgaray; José C Pachon Mateos; Silas Galvao Filho; Walter Reyes; Raúl Garillo
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

3.  Long-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan - A Multicenter Registry Study.

Authors:  Tze-Fan Chao; Chih-Hung Lai; Ta-Chuan Tuan; Tsu-Juey Wu; Jin-Long Huang; Chuen-Wang Chiou; Hsiang-Chiang Hsiao; Yenn-Jiang Lin; Jo-Nan Liao; Chi-Woon Kong; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

4.  Unique clinical features and long term follow up of survivors of sudden cardiac death in an Asian multicenter study.

Authors:  Pang-Shuo Huang; Jen-Fang Cheng; Wen-Chin Ko; Shu-Hsuan Chang; Tin-Tse Lin; Jien-Jiun Chen; Fu-Chun Chiu; Lian-Yu Lin; Ling-Ping Lai; Jiunn-Lee Lin; Chia-Ti Tsai
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.